Collegium Reaffirms FY23 Guidance
Portfolio Pulse from Benzinga Newsdesk
Collegium Pharmaceutical, Inc. has reaffirmed its full-year 2023 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA. The company expects product revenues to be between $565.0 to $580.0 million, adjusted operating expenses (excluding stock-based compensation) to be between $135.0 to $145.0 million, and adjusted EBITDA (excluding stock-based compensation) to be between $355.0 to $370.0 million.
August 04, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Collegium Pharmaceutical, Inc. has reaffirmed its FY23 guidance, which could provide stability and confidence to investors.
Reaffirming financial guidance is generally seen as a positive sign by investors as it indicates that the company is confident in its ability to meet its financial targets. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100